喘恶化的预测因子在血中异氨基酸细胞数量高低之间
Duong Duc Pham1, Yeonhee Kim1, Woo-Jung Song1
1Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
ERJ open research
|July 9, 2025
概括
喘恶化的预测因子在高和低血中乙氨基酸细胞计数 (BEC) 组之间有所不同. 虽然肺功能受损和女性性别是常见的,但吸烟和过敏预测高BEC喘的恶化,与低BEC喘不同.
科学领域:
- 肺部病理学 肺部病理学
- 过敏和免疫学 过敏和免疫学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 喘管理是复杂的,因为2型炎症表型的反应各不相同.
- 了解治疗前的个人资料可以帮助预测不同喘患者群体的恶化.
研究的目的:
- 为了比较与12个月喘恶化相关的治疗前形状,在患有高与低基线血中乙氨基酸细胞计数 (BEC) 的患者中.
主要方法:
- 包括438名高BEC (>300细胞·μL-1) 和231名低BEC (<150细胞·μL-1) 的患者.
- 收集了40个治疗前变量,并在12个月内跟踪恶化.
- 应用LASSO回归来确定每个BEC组中恶化的关键预测变量.
主要成果:
- 肺功能受损,女性性别和压力敏感性预测了两组患者的恶化.
- 高BEC组恶化与高BEC,吸烟史,烟草烟雾敏感性和过敏相关.
- 低BEC组恶化与高中性粒细胞计数,当前吸烟,结核病史和双重长效支气管扩展剂使用有关.
- 恶化预测模型在低BEC组中显示出更强的力量.
结论:
- 喘恶化概况在高和低预治疗BEC组之间表现出共同和独特的特征.
- 根据BEC水平量身定制恶化预测策略对于有效的喘管理至关重要.
相关概念视频
Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Asthma: Pathogenesis and Management
607
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
607
Asthma-III: Symptoms and Complications
2.6K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.6K
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
471
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
471


